"We will review the evidence and identify potential areas of improvement that can help reduce costs associated with UCB management while improving outcomes," write Daniel J. Lee, MD, and Sam S. Chang, MD.
Sam S. Chang, MD
Advertisement
Dr. Chang is Assistant Professor, Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tenn. He has received a research grant from Amgen and Cytogen, and is on the Speaker's Bureaus of Novartis and Sanofi.
Articles by Sam S. Chang, MD
Advertisement
Latest Updated Articles
- Cost considerations in the management of bladder cancer
Published: October 16th 2017 | Updated:
Advertisement
Advertisement
Trending on Urology Times
1
Choosing salvage therapy after prostate cancer focal ablation
2
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
3
SUO 2025 data confirm IsoPSA accuracy independent of mpMRI use
4
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
5
